866849-23-2

Usage

Uses

Used in Pharmaceutical Research and Development:
5-(4-METHYL-PIPERAZIN-1-YL)-INDAN-1-ONE is used as a starting material for the synthesis of biologically active compounds due to its structural features that facilitate the creation of new pharmaceuticals.
Used in Medicinal Chemistry Research:
5-(4-METHYL-PIPERAZIN-1-YL)-INDAN-1-ONE is used as a target for drug development because of its potential interactions with biological receptors, which can lead to the discovery of new therapeutic agents.
Used in Organic Chemistry:
5-(4-METHYL-PIPERAZIN-1-YL)-INDAN-1-ONE is used as a ketone derivative in organic chemistry for its potential to participate in various chemical reactions and the formation of new chemical entities.
Used in Pharmacology:
5-(4-METHYL-PIPERAZIN-1-YL)-INDAN-1-ONE is used in pharmacological studies to explore its range of pharmacological properties, which may contribute to the development of novel treatments for various conditions.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 700-84-5 5-fluoro-1-indanone 

Relevant academic research and scientific papers

1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel

The synthesis of a novel series of 1,4-dihydroindeno[1,2-c]pyrazoles with acetylene-type side chains is described. Optimization of those compounds as KDR kinase inhibitors identified 8, which displayed an oral activity in an estradiol-induced murine uterine edema model (ED50 = 3 mg/kg) superior to Sutent (ED50 = 9 mg/kg) and showed potent antitumor efficacy in an MX-1 human breast carcinoma xenograft tumor growth model (tumor growth inhibition = 90% at 25 mg/kg·day po). The compound was docked into a homology model of the homo-tetrameric pore domain of the hERG potassium channel to identify strategies to improve its cardiac safety profile. Systematic interruption of key binding interactions between 8 and Phe656, Tyr652, and Ser624 yielded 90, which only showed an IC50 of 11.6 μM in the hERG patch clamp assay. The selectivity profile for 8 and 90 revealed that both compounds are multitargeted receptor tyrosine kinase inhibitors with low nanomolar potencies against the members of the VEGFR and PDGFR kinase subfamilies.

TRICYCLIC PYRAZOLE KINASE INHIBITORS

Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.